ABSTRACT. Heparin-binding EGF-like growth factor (HB-EGF), a member of the EGF-family, is thought to be important for keratinocyte functions. HB-EGF is first synthesized as a membrane-anchored form, and its soluble form is released by ectodomain shedding. Here we investigate the role of HB-EGF in epidermal hyperplasia induced by all-trans retinoic acid (tRA) treatment. HB-EGF is normally expressed in epidermis of normal adult mice at very low levels, but topical tRA treatment results in epidermal hyperplasia, concomitant with the strong induction of HB-EGF expression in the suprabasal layer. tRA-induced epidermal hyperplasia was reduced both in the keratinocyte-specific HB-EGF null mice (K5-HB del/del ) and knock-in mice expressing the uncleavable mutant form of HB-EGF (HB uc/uc ), as compared with wild-type HB-EGF knock-in mice (HB lox/lox ). Among ErbB tyrosine kinase receptors, EGF receptor (EGFR) and ErbB2 were selectively activated by tRA treatment in skin from wild-type mice, while the activation of these ErbB receptors was significantly reduced in the skin of HB-EGF null mice. These results indicate that expression of HB-EGF and generation of its soluble form, followed by activation of EGFR and ErbB2, are pivotal processes in tRA-induced epidermal hyperplasia.
Introduction
Heparin-binding EGF-like growth factor (HB-EGF) is a member of the EGF-family of growth factors, including EGF, TGF-a, amphiregulin (AR), epiregulin (EPR), betacellulin (BTC), and epigen (Harris et al., 2003) . HB-EGF binds to and activates EGF receptor (EGFR/ErbB1) (Higashiyama et al., 1991) and ErbB4 (Elenius et al., 1997) . Theoretically, HB-EGF can activate not only EGFR and ErbB4 but also ErbB2 and ErbB3 since each ErbB receptor can form heterodimers following ligand binding (Holbro and Hynes, 2004) . Like other EGF-family members (Massague and Pandiella, 1993) , HB-EGF is first synthesized as a membrane-anchored form (proHB-EGF), and then cleaved at the juxtamembrane domain, resulting in the shedding of soluble HB-EGF (sHB-EGF) (Goishi et al., 1995) . sHB-EGF is a potent mitogen and chemoattractant for a number of cell types including vascular smooth muscle cells, fibroblasts and keratinocytes (Higashiyama et al., 1993; Raab and Klagsbrun, 1997) . ProHB-EGF forms a complex with other membrane proteins at the cell-cell contact site (Nakamura et al., 1995) and can transduce biological signals to neighboring cells in a non-diffusible manner (Iwamoto and Mekada, 2000) . Thus, proHB-EGF is also thought to be a biologically active molecule. HB-EGF has been implicated in a number of physiological and pathological processes (Raab and Klagsbrun, 1997) . Studies using mice lacking the HB-EGF gene or expressing a mutant form of HB-EGF revealed that HB-EGF is involved in heart development and function , normal lung morphogenesis (Jackson et al., 2003) , eyelid development (Mine et al., 2005) and wound healing processes in the skin (Shirakata et al., 2005) .
Retinoids, the derivatives of vitamin A, are important regulators of epithelial cell homeostasis. Retinoids are integral to cutaneous cellular proliferation and differentiation as evidenced by the characteristic hyperkeratosis observed in vitamin A deficiency (Miller, 1989) . All-trans retinoic acid (tRA) is the major biologically active metabolite of vitamin A. tRA and related synthetic retinoids have been used widely in the therapy of several skin disorders, including acne (Pedace and Stoughton, 1971) , photo-aged skin (Kligman et al., 1984) , and psoriasis (Goldfarb et al., 1988) . However, the effects of retinoids are often conflicting: retinoids can either stimulate or inhibit cell proliferation depending on the cell type affected or on the conditions used in cell cultivation (Amos and Lotan, 1990; Fisher and Voorhees, 1996; Rogers, 1997; Varani et al., 1989 Varani et al., , 1991 . Although the mechanism by which retinoids regulate the proliferation of epidermal cells is not completely understood, it has been shown that treatment of normal adult human skin and keratinocytes with tRA not only leads to thickening of the skin but also induces significant expression of several genes including HB-EGF (Bernard et al., 2002; Stoll and Elder, 1998; Varani et al., 2001) . Induction of HB-EGF has also been reported in the skin of mice treated topically with tRA (Chapellier et al., 2002; Xiao et al., 1999) . These studies suggested that HB-EGF might be involved in the signaling cascades underlying retinoid-induced epidermal hyperplasia.
Regarding the physiological function of HB-EGF in skin epidermis, we have shown that HB-EGF promotes keratinocyte migration but not proliferation during the eyelid development (Mine et al., 2005) and the skin wound-healing process (Shirakata et al., 2005) . Thus, it has remained unclear whether HB-EGF functions in keratinocyte proliferation in vivo when skin is treated with tRA, and which forms of HB-EGF (the membrane-anchored form or the soluble form) contribute to this process, if HB-EGF is involved. To address these issues, we investigated the process of tRA-induced epidermal hyperplasia using three types of HB-EGF mutant mice: keratinocyte-specific HB-EGF null mice (K5-HB del/del ) (Shirakata et al., 2005) , knockin mice expressing the uncleavable form of HB-EGF (HB uc/uc ) , and knock-in mice expressing wild-type HB-EGF as a wild-type control . Our results indicate that HB-EGF in its soluble form plays a pivotal role in tRA-induced epidermal hyperplasia. We also suggest that both EGFR and ErbB2 contribute to the proliferation of basal layer keratinocytes, which are stimulated by tRA-induced HB-EGF.
Materials and Methods

Mice
Generation and maintenance of HB-EGF null mice (HB del/del ), wild-type HB-EGF cDNA knock-in mice (HB lox/lox ) (used as an experimental wild-type control), keratinocyte-specific HB-EGF null mice (K5-HB del/del ), and knock-in mice expressing the uncleavable mutant form of HB-EGF (HB uc/uc ) were carried out as described previously Shirakata et al., 2005; Yamazaki et al., 2003) .
Retinoic-acid treatment protocol
Adult (8-12 week-old) female mice were used for all experiments. Prior to topical tRA treatment, hair was removed using an electric clipper under pentobarbital-anaesthetization. A single dose of tRA (200 nmol) was diluted with 400 ml of acetone just prior to use, and was applied daily to the entire back skin.
Histological analyses
For hematoxylin-eosin staining, skin samples were fixed with 4% paraformaldehyde (PFA), dehydrated and embedded in paraffin. Four-mm sections were stained with hematoxylin-eosin. For lacZ staining, the tissues were fixed with 4% PFA for 2 h, and then stained with 5-bromo-4-chloro-3-indolyl b-D-galactoside (X-gal). The stained tissues were fixed again 4% PFA, embedded in paraffin, sectioned at 4 mm and stained with nuclear fast red. For Ki67 staining, sections were treated with 10 mM sodium citrate buffer (pH 6.0) and heated to unmask the Ki67 antigen, and were incubated for 1 h at room temperature with an antibody against Ki67 (Novocastra) diluted 1:1000 in PBS. Biotinylated anti-rabbit IgG (Vector) diluted 1:500 in PBS was used as secondary antibody. Ki67 immunolocalization was performed using Vectastain Elite ABC and peroxidase substrate DAB kits (Vector). To determine the number of keratinocytes per unit length of epidermis, 5 micrographs from 5 independent sections were taken at high-power (×400) for each mouse skin. The number of keratinocytes was then counted on the 5 micrographs and pooled. The micrograph of the same 5 fields was also used to estimate the thickness of epidermis with Adobe Photoshop 6.0 software. Means±SD were calculated from skin samples of at least 5 animals of each genotype.
RT-PCR
RNA was isolated from skin samples using SV Total RNA Isolation System (Promega) according to the manufacturer's protocol. Reverse transcription was performed using ReverTra Ace (Toyobo) and random primers. PCR amplifications were carried out in a final volume of 25 ml containing an aliquot of the cDNA, 0.5 mM primers and 0.6U KOD Dash (Toyobo). The reaction mixture was kept at 95°C for 2 min for denaturation, followed by 26 amplification cycles for HB-EGF or 22 cycles for b-actin. Each cycle consisted of denaturation at 95°C for 10 sec, primer annealing at 64°C for 30 sec and extension at 72°C for 30 sec. The following primer pairs were used: for HB-EGF, 5'-GGTATCTGCACTCCCCGTG-GATGC-3' and 5'-ATGAAGCTGCTGCCGTCGGTGATGCTGA-3'; and for b-actin, 5'-GTGGGCCGCTCTAGGCACCA-3' and 5'-CGGTTGGCCTTAGGGTTCAGGGGG-3'. Quantitative PCR was performed in a real-time format on the 7700 ABI Prism Sequence Detector (Applied Biosystems). Gene specific primers and probes were purchased as Assays-on-Demand Gene Expression Products (Applied Biosystems). The assay IDs of HB-EGF, AR and TGF-a specific primers and probe were Mm00439307_m1, Mm00437583_m1 and Mm00446231_m1, respectively. 18S rRNA primers and probe were used to normalize the input of each cDNA sample. An aliquot of 5 ml of the reverse transcribed cDNA was added to 20 ml of reaction mixture containing 12.5 ml of Platinum Quantitative PCR SuperMix-UDG (Invitrogen), ROX Reference Dye (Invitrogen) and 1X Primers and Probe. The TaqMan cycling conditions consisted of 2 min degradation of the preamplified templates at 50°C and then 40 cycles of denaturation at 95°C for 15 sec, followed by annealing and extension at 58°C for 60 sec.
Immunoprecipitation and immunoblotting
For the detection of total ErbBs and phosphorylated ErbBs, back skin from 11 week-old wild-type (C57BL6/J) or HB del/del mice were treated with 200 nmol of tRA for indicated periods. The isolated full back skin was homogenized in lysis buffer . For detection of total ErbB1-4 proteins and phosphoErbB1-4 proteins in wild-type skin (Fig. 5) , the skin lysate was centrifuged at 20,000×g for 30 min, then each ErbB was immunoprecipitated from the supernatant. The precipitated ErbB and phospho-ErbB were detected by immunoblotting using anti-phosphotyrosine antibody as described previously . For detection of total ErbB1, 2 proteins and phosphoErbB1, 2 proteins in wild-type and HB del/del skin ( Fig. 6 ), the skin lysate was centrifuged at 20,000×g for 30 min, and then the supernatant was subjected to immunoblotting using anti-EGFR or antiErbB2 antibody (Santa Cruz Biotechnology), or anti-phospho-EGFR or anti-phospho-ErbB2 antibody (Cell Signaling Technology), respectively.
Results
Selective HB-EGF expression in the suprabasal keratinocytes of tRA-treated skin epidermis Topical application of tRA induced a marked increase in epidermal thickness (Fig. 1) . In addition, the number of Ki67-positive cells increased markedly (in parallel with skin thickening) in the tRA-treated skin (Fig. 1) . These proliferating cells were predominantly localized in the basal layer epidermis, as previously reported (Varani et al., 2001) .
In situ hybridization analysis indicated that topical tRA treatment of normal mouse skin induces HB-EGF mRNA expression exclusively in suprabasal keratinocytes (Xiao et al., 1999) . To confirm this, we analyzed the expression of HB-EGF in this process using a different technique. For the HB-EGF expression analysis, we used the keratinocytespecific heterozygotic (HB del/+ /K5-Cre (K5-HB del/+ )) HB-EGF knockout mice (Shirakata et al., 2005) . The targeting vector contains wild-type HB-EGF cDNA flanked by loxP sites linked to the LacZ gene as a reporter for the expression of HB-EGF, which is driven by the native HB-EGF promoter when HB-EGF cDNA is deleted by Cre recombinase . Thus, it is possible in K5-HB del/+ mice (and also in K5-HB del/del mice) to identify the expression of HB-EGF in the epidermal keratinocytes by staining for LacZ. The LacZ construct contains the nuclear targeting signal (NTR-LacZ) and staining the nuclei with X-Gal can readily identify cells expressing HB-EGF.
As shown in Fig. 2a , in untreated adult skin, HB-EGF expression was not detectable. However, in tRA-treated skin, HB-EGF expression was induced predominantly in the suprabasal keratinocytes. HB-EGF expression was apparent by 24 h following tRA treatment and the expression gradually increased over the subsequent days (Fig. 2b) . The EGFR-ligands including EGF (Weissman and Aaronson, 1983) , TGF-a (Coffey et al., 1987) , HB-EGF (Hashimoto et al., 1994) and AR (Cook et al., 1991) are known to stimulate keratinocyte proliferation. Among them, EGF expression has been reported to be unaffected by tRA treatment (Xiao et al., 1999) . Thus, to investigate the specific role of HB-EGF in tRA-induced epidermal hyperplasia, we examined the induction of TGF-a, AR, and HB-EGF mRNA in tRA-treated skin. tRA was topically applied to the back skin and the total RNA was harvested at several time points. The expression of each EGFR ligand was analyzed by quantitative RT-PCR. HB-EGF mRNA was rapidly induced after tRA treatment, reaching a peak of 5-fold induction at 24 h, whereas AR and TGF-a mRNAs were weakly induced, with a maximum increase of 1.3-fold and 3-fold even at 72 h, respectively (Fig. 2c) . These results suggest that HB-EGF is one of the major inducible genes of the EGFR-ligands examined in tRA-treated epidermis.
HB-EGF null mice show reduced epidermal hyperplasia
To examine directly the contribution of HB-EGF in tRA- induced skin hyperplasia, we compared the rate of hyperplasia between K5-HB del/del mice and the HB lox/lox mice after tRA treatment. We confirmed that tRA treatment induced HB-EGF mRNA expression in HB lox/lox skin but not in K5-HB del/del skin (Fig. 3) . In HB lox/lox skin, tRA treatment induced overt hyperplasia, while in K5-HB del/del skin the hyperplasia was significantly reduced ( Fig. 4a ; compare 'lox/lox' and 'K5-del/del'). To analyze these observations more quantitatively, the hyperplasia was assessed by measuring the epidermal thickness and the keratinocyte cell number (Fig. 4b) . The increase in skin thickness of HB lox/lox skin treated with tRA was approximately 4.1-fold, as compared with the vehicle-treated skin, whereas that of the K5-HB del/del skin demonstrated an approximately 2.8-fold increase. Thus, the rate of hyperplasia measured by the epidermal thickness in K5-HB del/del skin was 68% of the hyperplasia measured in tRA-treated control skins. The keratinocyte cell number of HB lox/lox skin treated with tRA was increased approximately 2.9-fold, as compared with the vehicle-treated skin, whereas that of the K5-HB del/del skin demonstrated an increase of approximately 2.5-fold. Thus, the rate of hyperplasia measured by the cell number in K5-HB del/del skin was 86% of the hyperplasia measured in tRA-treated control skins. These results indicate that HB-EGF is significantly involved in the skin hyperplasia induced by tRA treatment.
Ectodomain shedding is required for the function of HB-EGF in tRA-induced epidermal hyperplasia HB-EGF is first synthesized as a membrane-anchored form (proHB-EGF), and then the soluble form (sHB-EGF) is released from the cell surface by ectodomain shedding (Goishi et al., 1995) . Moreover, cell culture studies showed that proHB-EGF is biologically active as a juxtacrine growth mouse skins were untreated (day 0) or treated for 24 h (day 1), 48 h (day 2), or 72 h (day 3) with tRA. Skin sections were stained with X-gal. Scale bar: 100 mm. (c) The quantitative RT-PCR analysis of the induction of HB-EGF, amphiregulin and TGF-a mRNA. Normal adult mouse skins were treated with tRA. The y-axis represents relative mRNA levels expressed as fold induction over basal levels in vehicle-treated mice. The x-axis shows the time of sampling after tRA application. Data are mean +/-SD of triplicate measurements and were normalized against the 18S rRNA signal. pvalues were determined by Student's t-test HB-EGF versus Amphiregulin and TGF-a independently. Asterisks show statistically significant points in both cases (p<0.05). Fig. 3 . Expression of HB-EGF mRNA induced by tRA in HB-EGF mutant mice. Wild-type HB lox/lox mice (lox/lox), keratinocyte-specific HB-EGF null K5-HB del/del mice (K5-del/del) and uncleavable mutant HB uc/uc mice (uc/uc) were treated for 4 days with vehicle (-) or tRA (+). HB-EGF and b-actin mRNA expression were analyzed by RT-PCR. Disruption of HB-EGF mRNA expression in HB-EGF null skin, and normal HB-EGF mRNA expression in HB uc/uc mice were confirmed.
factor that signals to neighboring cells in a non-diffusible manner (Iwamoto and Mekada, 2000) . Thus, to investigate which form of HB-EGF is involved in tRA-induced skin hyperplasia, we analyzed this process by using knock-in mice that express an uncleavable mutant form of proHB-EGF (HB uc ) . We confirmed that tRA treatment induced HB-EGF mRNA expression in HB uc/uc skin, as it did in HB lox/lox skin (Fig. 3) , and that any soluble form of HB-EGF proteins was not detected in tRAtreated mutant skins .
As observed in K5-HB del/del skin, tRA-induced hyperplasia was significantly reduced in HB uc/uc skin as compared with the HB lox/lox skin ( Fig. 4a ; compare 'lox/lox' and 'uc/ uc'). The thickness of HB lox/lox skin treated with tRA was increased approximately 4.1-fold, in comparison to that of vehicle-treated, whereas that of HB uc/uc skin was increased approximately 2.5-fold (Fig. 4b) . Thus, the rate of hyperplasia measured by the epidermal thickness in HB uc/uc skin was 61% of the hyperplasia measured in tRA-treated control skins. The keratinocyte cell number of HB lox/lox skin treated with tRA was increased by approximately 2.9-fold, as compared with vehicle-treated skin, whereas that of the HB uc/uc skin was increased by approximately 2.2-fold (Fig.  4b) . Thus, the rate of hyperplasia measured by the cell number in HB uc/uc skin was 76% of the hyperplasia measured in tRA-treated control skins. These results indicate that ectodomain shedding of proHB-EGF is required in skin hyperplasia induced by tRA treatment, and that sHB-EGF but not proHB-EGF functions in this process.
HB-EGF-dependent EGFR and ErbB2 activation involved in tRA-induced epidermal hyperplasia
EGFR/ErbB1 is the receptor for HB-EGF (Higashiyama et al., 1991) and it is thought to be important for keratinocyte proliferation, differentiation, and migration (Jost et al., 2000) . EGFR can function not only in the homodimer form, but also in the heterodimer one with ErbB2, ErbB3, or ErbB4 (Holbro and Hynes, 2004) . To investigate which ErbB is activated in tRA-induced hyperplasia, we examined the tyrosine phosphorylation level of each ErbB receptor in tRA-treated or vehicle-treated wild-type skins (Fig. 5) . Tyrosine phosphorylation of EGFR (ErbB1) and ErbB2 was detected at 2 to 72 h after treatment with tRA, while phosphorylated EGFR and ErbB2 were not detected in vehicletreated skin. Phosphorylated ErbB3 was constitutively detected in both vehicle-and tRA-treated skin. Phosphorylated ErbB4 was not detected, consistent with the previous report that ErbB4 protein is either not present or is present at undetectable levels in the skin (Kiguchi et al., 2000; Plowman et al., 1993; Xian et al., 1997) . These results indicate that EGFR and ErbB2 are selectively activated in tRA-induced skin hyperplasia.
To determine whether tRA-induced EGFR and ErbB2 tyrosine phosphorylation is reduced in HB-EGF null mice, we compared the tyrosine phosphorylation level of EGFR and ErbB2 induced by tRA between wild-type and HB del/del skins. As shown in Fig. 6 , phosphorylation of both EGFR and ErbB2 was drastically reduced in HB del/del skin. These results provide evidence that HB-EGF transduces its signal by means of EGFR and ErbB2 activation, resulting in the promotion of keratinocyte proliferation in tRA-stimulated epidermal hyperplasia.
Discussion
Epidermal hyperplasia is the most prominent histological change in the skin observed after topical treatment with tRA. Previous studies have suggested that HB-EGF could be involved in the proliferation of keratinocytes following retinoid application using in vitro and ex vivo experimental systems (Chapellier et al., 2002; Stoll and Elder, 1998; Varani et al., 2001; Xiao et al., 1999) . In the present study, utilizing three types of mutant mice, HB lox/lox , K5-HB
and HB uc/uc , we present direct evidence indicating the substantial role of secreted HB-EGF in the process of tRAinduced epidermal hyperplasia: 1) topical tRA treatment resulted in prominent expression of HB-EGF in the suprabasal layer of thickened skin, 2) in HB-EGF null skins, tRA-induced hyperplasia was significantly reduced, 3) in the skin of mice expressing an uncleavable HB-EGF, hyperplasia was reduced to a level seen in the skin of HB-EGF null mice. Moreover, the present study demonstrated that tRA treatment resulted in phosphorylation of both EGFR and ErbB2 in wild-type skins, but that phosphorylation was significantly reduced in HB-EGF null skins, suggesting that the expression and ectodomain shedding of proHB-EGF, which generate a soluble form of HB-EGF, followed by HB-EGF-dependent activation of EGFR and ErbB2, are pivotal events contributing to tRA-induced epidermal hyperplasia.
EGFR is implicated as a critical factor in keratinocyte functions including proliferation, differentiation, and migration; however, the relationship between retinoid action and the function of other ErbB receptors in epidermal hyperplasia are not fully understood. It has been reported that antagonists for pan-ErbB tyrosine kinase receptors inhibited tRA-induced hyperplasia in organ-cultured human skin and proliferation of human epidermal keratinocytes in monolayer culture systems (Varani et al., 2001) . In this study, we first demonstrate that tRA rapidly and specifically induced autophosphorylation of both EGFR and ErbB2 in normal skin; however, this was significantly reduced in HB-EGF null skins, which indicates that HB-EGF activates both EGFR and ErbB2 in tRA-induced epidermal hyperplasia. HB-EGF does not bind ErbB2 or ErbB3. ErbB2 does not bind directly to any EGF-family ligands (Holbro and Hynes, 2004) . ErbB4, an additional binding receptor for HB-EGF and heteropartner of ErbB2 activation, was not detected in mice skin as reported previously (Kiguchi et al., 2000; Plowman et al., 1993; Xian et al., 1997) . These findings suggest the possibility that HB-EGF activates the heterodimer form of EGFR and ErbB2 in this process. However, it has been reported that immunostaining for ErbB2 and ErbB3 was accentuated in the upper spinous layers, and that . Reduced tyrosine phosphorylation of the EGFR and ErbB2 in tRA-treated HB-EGF null skin. Wild-type mice (+/+) and HB-EGF null (del/del) mice (two animals were independently used for each treatment) were treated with vehicle or tRA. Twenty-four hours after treatment, the skin was lysed, and total EGFR (ErbB1) and ErbB2, and phospho-EGFR and phospho-ErbB2 in the lysate was analyzed by Western blotting using anti-EGFR and anti-ErbB2 antibody, or anti-phospho-EGFR and antiphospho-ErbB2 antibody, respectively.
EGFR was strongly labeled in basal cells in human skin epidermis (Piepkorn et al., 2003) . This suggests an alternative possibility that HB-EGF first activates EGFR in the basal cells, resulting in induction of other EGF-family ligands, such as neuregulins, that can activate ErbB2/ErbB3 heterodimer in the upper spinous layers.
Confirming the findings of a previous study (Xiao et al., 1999) , in the present study we clearly showed that HB-EGF is expressed exclusively in the suprabasal keratinocytes in tRA-induced epidermal hyperplasia. Moreover, EGFR and ErbB2 were activated by tRA treatment, in an HB-EGFdependent manner. EGFR localizes mainly in the basal keratinocytes (King et al., 1990; Vassar and Fuchs, 1991) , and the cells that predominantly proliferate in epidermis localize in the basal layer. These results imply that HB-EGF, expressed in the suprabasal layer, has to translocate to the basal layer of epidermis in order to promote EGFR activation and proliferation of basal layer keratinocytes. Using HB uc/uc mice, we observed that the epidermal hyperplasia was inhibited to a level equivalent to that seen in HB-EGF null mice, indicating that HB-EGF functions in this process in the soluble form, and not the membrane-anchored form. Indeed, we have previously shown that sHB-EGF is produced in tRA-treated epidermis . In addition, our preliminary experiment demonstrated that the phosphorylation level of EGFR and ErbB2 was dramatically reduced in HB uc/uc mice upon tRA-treatment (data not shown). These results suggest the following model of HB-EGF action in tRA-induced epidermal hyperplasia: 1) topical tRA treatment of skin induces the expression of proHB-EGF in the suprabasal layer of keratinocytes, 2) proHB-EGF is processed by an ectodomain shedding mechanism, resulting in the release of sHB-EGF, 3) sHB-EGF translocates from the suprabasal layer to the basal layer epidermis, and 4) translocated sHB-EGF activates EGFR localized in the basal layer and promotes proliferation of the basal layer keratinocytes, resulting in epidermal hyperplasia.
In skin epidermis, keratinocytes are stratified and the cells contact each other laterally via tight junctions (Tsukita and Furuse, 2002) . How can sHB-EGF translocate across these cell-cell junctions? It has been reported, both in cultured keratinocytes and in the skin, that retinoids cause fragility of this cell-cell contact through decreased numbers of tonofilaments in keratinocytes and desmosomal attachments in the epidermis (Hatakeyama et al., 2004; Peck et al., 1977; Wanner et al., 1999; Williams et al., 1981) . This suggests that tRA treatment induces epidermal fragility, and as a result, sHB-EGF might be able to translocate through gaps between the keratinocytes to the basal layer.
Phosphorylation levels of EGFR and ErbB2 remained almost at a basal level in tRA-treated HB-EGF null skins, suggesting that HB-EGF is a major factor for tRA-induced EGFR/ErbB2 activation. On the other hand, keratinocytespecific HB-EGF null mice clearly showed a significant reduction of epidermal hyperplasia following topical tRA treatment; however, the defect was incomplete. These findings suggest that factor(s) other than HB-EGF might be involved in tRA-induced keratinocyte proliferation after activation of EGFR and ErbB2. Although HB-EGF mRNA expression was predominantly induced among the EGFRligands tested here (HB-EGF, AR, and TGF-a), other EGF family ligands that were not examined (EGF, EPR, BTC, epigen, and neuregulins) might also be involved in this process. As has been reported previously (Hashimoto et al., 1994) , HB-EGF may act as an autocrine growth factor, which induces other EGF-family growth factors in tRAinduced keratinocyte proliferation. Partial reduction of tRAinduced hyperplasia in HB-EGF null skin also suggests that other signaling pathway(s), distinct from the EGF familyErbB axis pathway, might be involved in this process. Consistent with this view, it has been reported that tRA does not increase HB-EGF expression in RARg -/-and RARg sb-/-mice, whereas it still exerts a degree of proliferative effect on the epidermis of these mice (Chapellier et al., 2002) . Further, it has been shown that expression of keratinocyte growth factor is stimulated by tRA in cultured gingival fibroblasts (Mackenzie and Gao, 2001) . Further studies are necessary to reveal the whole molecular mechanism involved in epidermal cell proliferation regulated by retinoids.
